CBAY
Income statement / Annual
Last year (2023), CymaBay Therapeutics, Inc.'s total revenue was $31.07 M,
and the percentage change from the previous year is not available.
In 2023, CymaBay Therapeutics, Inc.'s net income was -$105.37 M.
See CymaBay Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$31.07 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10.00 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$681,000.00 |
$710,000.00 |
$688,000.00 |
$632,000.00 |
$800,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$30.39 M |
-$710,000.00 |
-$688,000.00 |
-$632,000.00 |
-$800,000.00 |
$0.00 |
$10.00 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.98 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
| Research and Development
Expenses |
$80.12 M
|
$68.00 M
|
$64.54 M
|
$35.88 M
|
$83.84 M
|
$58.12 M
|
$18.94 M
|
$15.94 M
|
$17.03 M
|
$15.82 M
|
| General & Administrative
Expenses |
$51.95 M
|
$25.12 M
|
$23.04 M
|
$17.43 M
|
$19.24 M
|
$14.38 M
|
$12.39 M
|
$9.65 M
|
$8.87 M
|
$8.19 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$51.95 M
|
$25.12 M
|
$23.04 M
|
$17.43 M
|
$19.24 M
|
$14.38 M
|
$12.39 M
|
$9.65 M
|
$8.87 M
|
$8.19 M
|
| Other Expenses |
$1.76 M |
$0.00 |
$0.00 |
$0.00 |
$5.08 M |
-$3.29 M |
-$5.77 M |
$76,000.00 |
$11.12 M |
-$7.23 M |
| Operating Expenses |
$132.07 M |
$93.11 M |
$87.58 M |
$53.31 M |
$103.08 M |
$72.51 M |
$31.33 M |
$25.59 M |
$25.90 M |
$24.01 M |
| Cost And Expenses |
$132.75 M |
$93.11 M |
$87.58 M |
$53.31 M |
$103.08 M |
$72.51 M |
$31.33 M |
$25.59 M |
$25.90 M |
$24.01 M |
| Interest Income |
$13.49 M |
$2.02 M |
$167,000.00 |
$1.62 M |
$5.34 M |
$3.99 M |
$621,000.00 |
$176,000.00 |
$160,000.00 |
$74,000.00 |
| Interest Expense |
$18.95 M |
$14.91 M |
$2.58 M |
$0.00 |
$0.00 |
$336,000.00 |
$1.08 M |
$1.34 M |
$913,000.00 |
$755,000.00 |
| Depreciation &
Amortization |
$681,000.00
|
$2.02 M
|
$855,000.00
|
-$778,000.00
|
$10.42 M
|
$105,000.00
|
$35,000.00
|
$29,000.00
|
$22,000.00
|
$18,000.00
|
| EBITDA |
-$85.74 M
|
-$92.40 M
|
-$86.73 M
|
-$50.35 M
|
-$108.15 M
|
-$71.70 M
|
-$26.44 M
|
-$25.31 M
|
-$14.59 M
|
-$24.01 M
|
| EBITDA Ratio |
-3.25 |
0 |
0 |
0 |
0 |
0 |
-2.64 |
0 |
0 |
0 |
| Operating Income Ratio
|
-3.27
|
0
|
0
|
0
|
0
|
0
|
-2.13
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$3.69 M
|
-$12.89 M
|
-$2.42 M
|
$1.62 M
|
$5.34 M
|
-$43,000.00
|
-$6.23 M
|
-$1.09 M
|
$10.37 M
|
-$7.91 M
|
| Income Before Tax |
-$105.37 M |
-$106.00 M |
-$90.00 M |
-$50.99 M |
-$102.81 M |
-$72.55 M |
-$27.56 M |
-$26.67 M |
-$15.53 M |
-$31.92 M |
| Income Before Tax Ratio
|
-3.39
|
0
|
0
|
0
|
0
|
0
|
-2.76
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$12.89 M |
$2.58 M |
-$2.32 M |
-$572,000.00 |
$293,000.00 |
-$4.69 M |
$1.41 M |
$12.03 M |
-$6.47 M |
| Net Income |
-$105.37 M |
-$118.89 M |
-$92.58 M |
-$48.67 M |
-$102.24 M |
-$72.55 M |
-$27.56 M |
-$26.67 M |
-$15.53 M |
-$31.92 M |
| Net Income Ratio |
-3.39 |
0 |
0 |
0 |
0 |
0 |
-2.76 |
0 |
0 |
0 |
| EPS |
-0.99 |
-1.35 |
-1.3 |
-0.71 |
-1.53 |
-1.25 |
-0.79 |
-1.14 |
-0.82 |
-2.65 |
| EPS Diluted |
-0.99 |
-1.35 |
-1.3 |
-0.71 |
-1.53 |
-1.25 |
-0.79 |
-1.14 |
-0.82 |
-2.65 |
| Weighted Average Shares
Out |
$106.20 M
|
$87.80 M
|
$71.06 M
|
$68.89 M
|
$67.03 M
|
$57.81 M
|
$34.88 M
|
$23.40 M
|
$18.90 M
|
$12.04 M
|
| Weighted Average Shares
Out Diluted |
$106.20 M
|
$87.80 M
|
$71.06 M
|
$68.89 M
|
$67.03 M
|
$57.84 M
|
$34.90 M
|
$23.45 M
|
$18.92 M
|
$12.05 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
